Jul 17,2021

Study Compares Nerivio to Standard Care Medications for Acute Treatment of Migraine in Adolescents

Theranica, a prescribed digital therapeutics company developing advanced electroceuticals for migraine and other pain conditions, announced the publication of a study in Pain Medicine that compared adolescent response to migraine medications to their response to Remote Electrical Neuromodulation (REN) administered by Nerivio®. The study found statistically significant differences in post 2-hour pain freedom and pain relief outcomes, in favor of REN (Nerivio). It also found an increase in pain relief for patients who used Nerivio.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jul 26,2021

Cognito Therapeutics Presents New Clinical Data Demonstrating Disease-Modifying Effects of Gamma Frequency Neuro-modulation on Cognitive Function and Brain Atrophy in Alzheimer’s Disease at AAIC 2021

Cognito Therapeutics, a Phase 3-ready neuro-physiology company developing a new class of disease-modifying digital therapeutics to treat neurodegenerative disorders, presented key findings from clinical research involving its lead digital therapeutic candidate at the Alzheimer’s Association International Conference® 2021 (AAIC®), virtual and in-person in Denver, Colorado, July 26-30, 2021.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Jul 28,2021

Pear Therapeutics Announces Publication of Healthcare Resource Utilization Data Analysis Showing Real-World Cost Impact of reSET-O® in Treating Opioid Use Disorder

Pear Therapeutics, Inc., today announced publication of a new analysis demonstrating the real-world cost impact of reSET-O®, the first and only FDA-authorized Prescription Digital Therapeutic (PDT) for the treatment of opioid use disorder (OUD). The real-world retrospective analysis, published in the peer-reviewed journal Hospital Practice, showed a substantial reduction in medical costs of -$2,385 per patient over 6 months in patients who engaged with reSET-O1. In comparison, patients who did not redeem/engage with reSET-O beyond week 1 had a net cost increase of $353.80 per patient during the same time period.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Jul 29,2021

Digital MSK therapy tool Kaia gives equally reliable exercise recommendations as physiotherapists, study finds

A new study published by JMIR found that the digital physical therapy tool Kaia was able to suggest exercise corrections with comparable accuracy to a physiotherapist. Participants in the study used Kaia’s app, formerly called Motion Coach, which includes automated, real-time exercise feedback that is tracked with the user’s smartphone camera or tablet. The small study examined the corrections and exercise suggestions that the app gave patients against physiotherapists' evaluations.

CLINICAL STUDY

#mobile app

#virtual care

View Analyst & Ambassador Comments
Go to original news
Aug 06,2021

Study: Adults Over 65 Years More Engaged with Digital Coaching Platform Than Younger Adults

Lark Health, a healthcare company that helps people prevent and manage chronic conditions through an AI-powered platform, today announced results from its latest study, which examined the engagement of adults 65 years and older with a digital health platform compared to that of adults aged 35 to 64 years. The research was published in the peer-reviewed journal Frontiers in Digital Health.

CLINICAL STUDY

#coaching

#telehealth

#mobile app

View Analyst & Ambassador Comments
Go to original news
Aug 13,2021

DarioHealth Presents New Study Demonstrating Significant Clinical Impact Of Personalized Digital Interventions Based On Real-Time Data

DarioHealth Corp. a pioneer in the global digital therapeutics market, announced a new study at the American Association of Diabetes Care and Education Specialists (ADCES) annual conference demonstrating the impact of Dario’s intelligent personalization platform. Dario’s latest presentation examined the impact of personalized clinical interventions delivered in real-time through the company’s digital therapeutics platform. To understand the potential impact, the study tracked a group of 3,609 Dario members including people with Type 2 diabetes, both insulin and non-insulin dependent, with recent clusters of high blood glucose readings, an indicator of poor health behaviors.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Sep 01,2021

Pear Therapeutics Announces Publication Of Cost-Utility Data Showing Quality Of Life And Cost Reduction With reSET-O

Pear Therapeutics, Inc., today announced publication of a cost-utility model evaluating the cost impact and treatment retention effectiveness of reSET-O®. In the study, a third-party payer-perspective decision analytic model evaluated the cost-effectiveness of reSET-O relative to treatment-as-usual (TAU – transmucosal buprenorphine, face-to-face counseling and contingency management) alone over 12 weeks. Results of this model showed population-level gains in quality-adjusted life years at a lower cost with reSET-O treatment vs TAU alone. In addition to clinical value, these results show the limited economic risk of reSET-O as an adjunct to TAU.

CLINICAL STUDY

#pdt

View Analyst & Ambassador Comments
Go to original news
Sep 01,2021

Study Demonstrates Combining Digital Therapeutics for Insomnia and IAPT Therapy Improves Sleep, Anxiety, and Depression More Than Therapy Alone

Big Health, a digital therapeutics company dedicated to helping millions back to good mental health, and the Oxford Health NHS Foundation Trust today announced a joint study published in the Behaviour Research and Therapy journal showing almost two-thirds [65 percent] of people seeking treatment for anxiety or depression and who had sleep difficulty saw their mental health improve substantially more by combining enrollment in Sleepio, Big Health’s digital therapeutic for insomnia, with NHS Improving Access to Psychological Therapies programme (IAPT) care, when compared to IAPT care alone.

CLINICAL STUDY

#mobile app

#cbt

View Analyst & Ambassador Comments
Go to original news
Sep 08,2021

Digital Therapeutic Relieves PTSD Symptoms in 88 Percent of Military Veterans and Sexual Assault Victims Studied

Freespira, Inc., the maker of the first FDA-cleared digital therapeutic to significantly reduce or eliminate symptoms of panic attacks, panic disorder and post-traumatic stress disorder (PTSD) in only 28 days, today announced findings from a study in the September issue of the Journal of Applied Psychophysiology and Biofeedback demonstrating that PTSD severity can be significantly reduced with its first-of-its-kind treatment.

CLINICAL STUDY

#coaching

View Analyst & Ambassador Comments
Go to original news
Sep 09,2021

Propeller Health research showcased at ERS International Congress 2021

This year, the ERS accepted four abstracts authored by Propeller and its research partners ResMed and Novartis. Read brief summaries of each abstract below or click their titles to view them online.

CLINICAL STUDY

#mobile app

#connected device

View Analyst & Ambassador Comments
Go to original news
Subscribe to CLINICAL STUDY